about
sameAs
P3354
P3355
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathwaysThe discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivoMEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion.Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib).A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration
P921
Q33801421-64F07CDC-765F-4F2A-9224-3C05B7546E72Q34014364-36EFA731-F067-4AE1-B378-87BB64A486C6Q34106382-D513A5B9-E781-48DE-A6C3-9F058814A921Q34109756-72DFB02F-2AFE-4509-B675-ACE7123CCD83Q35197507-87C8D402-40B4-40FC-BAA9-B9610507C8DDQ35891699-A3D71DDF-E1D5-46CD-920E-D08784DFDFD0Q35987649-31754A6B-8FB8-41FE-BDFE-480BD9A7F284Q36021572-C727D822-EB2B-4E4A-BEDF-F1922928CA52Q38491964-459E26F9-48A2-4D8E-AC7F-190205ED9C2DQ43136770-E7A841AF-520C-4287-9363-0D2284DF25BDQ43237718-7AF87773-4B4A-484B-A9D2-5686E8E8D3CAQ46072194-AD97B161-E6CD-40E4-9ED1-AB0BC74DDFD3Q51068050-A2AC0513-6B4D-4B1E-A52D-4395897A6685Q54500306-01027581-D7E9-4836-A630-D4D0F5889FE8Q80194445-63FB8694-2BD3-4BAD-B51C-D3D8BBB7069C
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
PD-0325901
@en
type
label
PD-0325901
@en
altLabel
N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
@en
PD 0325901
@en
PD 325901
@en
PD-325901
@en
PD0325901
@en
prefLabel
PD-0325901
@en
P592
P661
P662
P683
P1579
P2017
C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@@H](CO)O
P2067
P231
391210-10-9
P232
P233
C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOCC(CO)O
P234
1S/C16H14F3IN2O4/c17-11-3-2-10 ...... -24H,6-7H2,(H,22,25)/t9-/m1/s1
P235
SUDAHWBOROXANE-SECBINFHSA-N
P2566
100.213.070
P274
C₁₆H₁₄F₃IN₂O₄
P3117
DTXSID0044024
P592
CHEMBL507361
P652
86K0J5AK6M